Ryvu Therapeutics Valuation
Is RVU undervalued compared to its fair value, analyst forecasts and its price relative to the market?
Valuation Score
4/6Valuation Score 4/6
Below Fair Value
Significantly Below Fair Value
Price-To-Sales vs Peers
Price-To-Sales vs Industry
Price-To-Sales vs Fair Ratio
Analyst Forecast
Share Price vs Fair Value
What is the Fair Price of RVU when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.
Below Fair Value: RVU (PLN50.7) is trading below our estimate of fair value (PLN91.02)
Significantly Below Fair Value: RVU is trading below fair value by more than 20%.
Key Valuation Metric
Which metric is best to use when looking at relative valuation for RVU?
Other financial metrics that can be useful for relative valuation.
| What is RVU's n/a Ratio? | |
|---|---|
| n/a | 0x |
| n/a | n/a |
| Market Cap | zł1.17b |
| Key Statistics | |
|---|---|
| Enterprise Value/Revenue | 14.1x |
| Enterprise Value/EBITDA | -10.9x |
| PEG Ratio | n/a |
Price to Sales Ratio vs Peers
How does RVU's PS Ratio compare to its peers?
| Company | Forward PS | Estimated Growth | Market Cap |
|---|---|---|---|
| Peer Average | 3.7x | ||
SLV Selvita | 3.6x | 19.9% | zł1.3b |
CLN Celon Pharma | 3.8x | 6.6% | zł823.0m |
BICO BICO Group | 1.3x | 10.4% | kr3.1b |
SVE Synthaverse | 5.9x | n/a | zł348.4m |
RVU Ryvu Therapeutics | 17.4x | 51.6% | zł1.2b |
Price-To-Sales vs Peers: RVU is expensive based on its Price-To-Sales Ratio (17.4x) compared to the peer average (9.2x).
Price to Earnings Ratio vs Industry
How does RVU's PE Ratio compare vs other companies in the European Life Sciences Industry?
Price-To-Sales vs Industry: RVU is expensive based on its Price-To-Sales Ratio (17.4x) compared to the European Life Sciences industry average (4.5x).
Price to Sales Ratio vs Fair Ratio
What is RVU's PS Ratio compared to its Fair PS Ratio? This is the expected PS Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.
| Fair Ratio | |
|---|---|
| Current PS Ratio | 17.4x |
| Fair PS Ratio | 20x |
Price-To-Sales vs Fair Ratio: RVU is good value based on its Price-To-Sales Ratio (17.4x) compared to the estimated Fair Price-To-Sales Ratio (20x).
Analyst Price Targets
What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?
| Date | Share Price | Average 1Y Price Target | Dispersion | High | Low | 1Y Actual price | Analysts |
|---|---|---|---|---|---|---|---|
| Current | zł50.70 | zł73.13 +44.2% | 9.7% | zł80.00 | zł64.00 | n/a | 4 |
| May ’25 | zł49.50 | zł73.13 +47.7% | 9.7% | zł80.00 | zł64.00 | n/a | 4 |
| Apr ’25 | zł55.20 | zł71.88 +30.2% | 8.5% | zł80.00 | zł64.00 | n/a | 4 |
| Mar ’25 | zł59.00 | zł73.13 +23.9% | 9.7% | zł80.00 | zł64.00 | n/a | 4 |
| Feb ’25 | zł56.00 | zł71.43 +27.5% | 12.1% | zł80.00 | zł61.70 | n/a | 4 |
| Jan ’25 | zł57.50 | zł71.43 +24.2% | 12.1% | zł80.00 | zł61.70 | n/a | 4 |
| Dec ’24 | zł59.70 | zł71.43 +19.6% | 12.1% | zł80.00 | zł61.70 | n/a | 4 |
| Nov ’24 | zł60.50 | zł70.43 +16.4% | 10.5% | zł80.00 | zł61.70 | n/a | 4 |
| Oct ’24 | zł65.20 | zł72.57 +11.3% | 11.1% | zł81.00 | zł61.70 | n/a | 3 |
| Sep ’24 | zł60.90 | zł72.57 +19.2% | 11.1% | zł81.00 | zł61.70 | n/a | 3 |
| Aug ’24 | zł58.30 | zł72.57 +24.5% | 11.1% | zł81.00 | zł61.70 | n/a | 3 |
| Jul ’24 | zł60.40 | zł72.23 +19.6% | 10.7% | zł80.00 | zł61.70 | n/a | 3 |
| Jun ’24 | zł56.00 | zł72.23 +29.0% | 10.7% | zł80.00 | zł61.70 | n/a | 3 |
| May ’24 | zł56.00 | zł72.23 +29.0% | 10.7% | zł80.00 | zł61.70 | zł49.50 | 3 |
| Apr ’24 | zł59.20 | zł72.23 +22.0% | 10.7% | zł80.00 | zł61.70 | zł55.20 | 3 |
| Mar ’24 | zł63.70 | zł62.90 -1.3% | 21.5% | zł80.00 | zł47.00 | zł59.00 | 3 |
| Feb ’24 | zł53.40 | zł55.70 +4.3% | 15.6% | zł64.40 | zł47.00 | zł56.00 | 2 |
| Jan ’24 | zł49.25 | zł55.70 +13.1% | 15.6% | zł64.40 | zł47.00 | zł57.50 | 2 |
| Dec ’23 | zł55.90 | zł55.70 -0.4% | 15.6% | zł64.40 | zł47.00 | zł59.70 | 2 |
| Nov ’23 | zł41.00 | zł55.70 +35.9% | 15.6% | zł64.40 | zł47.00 | zł60.50 | 2 |
| Oct ’23 | zł33.30 | zł55.70 +67.3% | 15.6% | zł64.40 | zł47.00 | zł65.20 | 2 |
| Sep ’23 | zł31.85 | zł55.70 +74.9% | 15.6% | zł64.40 | zł47.00 | zł60.90 | 2 |
| Aug ’23 | zł31.10 | zł55.70 +79.1% | 15.6% | zł64.40 | zł47.00 | zł58.30 | 2 |
| Jul ’23 | zł27.00 | zł55.70 +106.3% | 15.6% | zł64.40 | zł47.00 | zł60.40 | 2 |
| Jun ’23 | zł34.50 | zł55.70 +61.4% | 15.6% | zł64.40 | zł47.00 | zł56.00 | 2 |
| May ’23 | zł39.80 | zł55.70 +39.9% | 15.6% | zł64.40 | zł47.00 | zł56.00 | 2 |
Analyst Forecast: Target price is more than 20% higher than the current share price and analysts are within a statistically confident range of agreement.